Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Pharmaceutical
Novo Seeds, the early-stage investment and company creation team of Novo Holdings, has invested in a new portfolio company Hemab ApS, which is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders. 14 December 2020
Pharmaceutical
UK provider of development services to drugmakers Ergomed today announced the acquisition of MS Clinical Services (MediSource), a specialized clinical research organization (CRO) based in Houston, Texas, USA. 14 December 2020
Pharmaceutical
British pharma major AstraZeneca looks set to make the biggest pharma M&A deal of 2020, on Saturday announcing that it plans to expand further into the rare diseases sector. 13 December 2020
Biotechnology
US biotech major Gilead Sciences seems to have an insatiable appetite for M&A this year, as it notches up a fifth acquisition deal today. 10 December 2020
Biotechnology
Boehringer Ingelheim today said it has signed a binding agreement to acquire all the shares of NBE-Therapeutics, a private, clinical-stage Swiss I-O biotech focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC platform. 10 December 2020
Pharmaceutical
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall, the sector will start the year from a position of strength, according to the Evaluate Vantage 2021 Preview, published today. 10 December 2020
Biotechnology
Overland Pharmaceuticals has announced its official launch with a mission to bring innovative medicines to underserved patients in Asia and around the world. 9 December 2020
Biotechnology
Family-owned pharma major Boehringer Ingelheim has signed an agreement to acquire all shares of fellow Germany-based biotech company Labor Dr Merk & Kollegen. 9 December 2020
Biotechnology
US biotech Syros Pharmaceuticals has acquired SY-2101, a clinical-stage drug candidate formerly known as ORH-2014, from Orsenix. 7 December 2020
Pharmaceutical
While November was an action-packed month so far as coronavirus vaccine developments were concerned, the world of pharmaceutical mergers and acquisitions (M&A) was very quiet. 2 December 2020
Biotechnology
British contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has announced a new strategic partnership with ADC Biotechnology (ADC Bio), a UK based biotechnology company specializing in antibody drug conjugates. 2 December 2020
Generics
France-based Provepharm Life Solutions today revealed it has acquired Apollo Pharmaceuticals USA, company that specializes in the commercialization of sterile injectable products for hospital use. 2 December 2020
Pharmaceutical
UK-headquartered Indivior says it has reviewed the £1.07 billion ($1.4 billion) claim by former parent Reckitt Benckiser Group filed against the company in the Commercial High Court in London on November 13, 2020. 1 December 2020
Pharmaceutical
Japanese drugmaker Takeda is to make Nihon Pharmaceutical a wholly-owned subsidiary through a simple share exchange worth around $52 million. 25 November 2020
Pharmaceutical
US pharma giant Merck & Co says it will acquire all outstanding shares of OncoImmune for an upfront payment in cash. 24 November 2020
Biotechnology
German drugmaker Bayer has generally preferred in-licensing deals and other collaborations to multi-billion dollar acquisitions, so executives must have been highly impressed by what they saw of Asklepios BioPharmaceutical (AskBio) to spend $2 billion upfront on buying the US biotech, along with up to $2 billion more depending on certain milestones. 23 November 2020
Generics
Development Partners International (DPI) through its ADP III fund, CDC Group, the UK’s publicly-owned impact investor, and the European Bank for Reconstruction and Development (EBRD) have joined forces in a ground-breaking deal to create a major new player in the pan-African pharmaceuticals industry. 23 November 2020
Pharmaceutical
Clinical trial results featured in last week’s news, some good and others not so good. Cytokinetics and Amgen presented mixed Phase III data on their omecamtiv mecarbil in heart failure. Meantime, US biotech Moderna created another wave of COVID-19 euphoria, releasing strong new data on its vaccine candidate mRNA-1273. But there was a major disappointment for BrainStorm Cell Therapeutics with the Phase III study of its amyotrophic lateral sclerosis (ALS) candidate NurOwn. Elsewhere, questions were raised about the price being paid for the remaining shares in Urovant, and its over-active bladder (OAB) lead candidate vibregon, by Sumitovant Biopharma, a unit of Japan’s Sumitomo Dainippon. 22 November 2020
Biotechnology
Life sciences investment trust Syncona has announced the foundation of a new Syncona company, Purespring Therapeutics, with a £45.0 million ($59.5 million) Series A financing. 21 November 2020
Biotechnology
The US regulator has said a submission from Bristol Myers Squibb for lisocabtagene maraleucel (liso-cel) will be delayed. 17 November 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze